Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Refractive outcomes of ray tracing IOL calculation in Asian eyes

Search Title by author or title

Session Details

Session Title: IOL Power Calculations

Session Date/Time: Sunday 11/09/2016 | 16:00-18:00

Paper Time: 16:12

Venue: Hall C2

First Author: : S.Srivannaboon THAILAND

Co Author(s): :    C. Chirapapaisan                    

Abstract Details

Purpose:

To evaluate the accuracy of the Ray Tracing formula (Okulix) with OA-2000 and compare with other formulas

Setting:

Department of Ophthalmology, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Methods:

30 eyes (30 cataract patents) were enrolled in this study. Ocular biometry was performed using OA-2000 biometer and CASIA tomographer. The IOL power was calculated using Hoffer-Q, Holladay 1 and SRK/T formulas with the optimized IOL constant for ZCB00 model. The Okulix Ray Tracing formula was also calculated with and without posterior corneal data. Mean Arithmetic Error (MAE), Mean Absolute Error (MAbE) and Median Absolute Error (MedAbE) were calculated and compared between formulas.

Results:

The MAE for all formulas were closed to zero (0.03 to 0.06 D). The MAbE for SRK/T, Hoffer Q, Holladay 1 and Okulix with and without posterior corneal data were 0.37, 0.42, 0.39, 0.43 and 0.35 diopter respectively. The MedAbE for SRK/T, Hoffer Q, Holladay 1 and Okulix with and without posterior corneal data were 0.32, 0.38, 0.29, 0.40 and 0.31 diopter respectively.

Conclusions:

The ray tracing IOL formula did not show any superiority in refractive outcomes when compared to current IOL formulas. Adding posterior corneal data to the ray tracing IOL formula showed slight improve in the refractive outcomes.

Financial Disclosure:

NONE

Back to previous